Chung-Pin Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8197689/publications.pdf

Version: 2024-02-01

96 3,957 28 60 papers citations h-index g-index

97 97 97 6406
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet, The, 2016, 387, 545-557.	13.7	878
2	A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European Journal of Cancer, 2014, 50, 2072-2081.	2.8	283
3	Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2020, 38, 3185-3194.	1.6	233
4	Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study. International Journal of Radiation Oncology Biology Physics, 2003, 57, 98-104.	0.8	197
5	Pulmonary tuberculosis increases the risk of lung cancer. Cancer, 2011, 117, 618-624.	4.1	145
6	How different is the care of terminal pancreatic cancer patients in inpatient palliative care units and acute hospital wards? A nationwide population-based study. BMC Palliative Care, 2016, 15, 1.	1.8	135
7	APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant <i>nab</i> -paclitaxel plus gemcitabine (< >nab-paclitaxel plus gemcitabine (< >nab-paclitaxel plus gemcitabine (G) for surgically resected pancreatic adenocarcinoma Journal of Clinical Oncology, 2019, 37, 4000-4000.	1.6	125
8	High Blood Pressure and All-Cause and Cardiovascular Disease Mortalities in Community-Dwelling Older Adults. Medicine (United States), 2015, 94, e2160.	1.0	108
9	Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma. JCl Insight, 2017, 2, .	5.0	102
10	Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget, 2015, 6, 18162-18173.	1.8	90
11	Association of Body Mass Index with All-Cause and Cardiovascular Disease Mortality in the Elderly. PLoS ONE, 2014, 9, e102589.	2.5	79
12	Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Investigational New Drugs, 2018, 36, 683-695.	2.6	75
13	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma. JAMA Oncology, 2017, 3, 235.	7.1	74
14	Determinants of Long-Term Care Services among the Elderly: A Population-Based Study in Taiwan. PLoS ONE, 2014, 9, e89213.	2.5	58
15	A new ALBIâ€based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver International, 2019, 39, 1704-1712.	3.9	58
16	Spider angiomas in patients with liver cirrhosis: Role of vascular endothelial growth factor and basic fibroblast growth factor. World Journal of Gastroenterology, 2003, 9, 2832.	3.3	53
17	Smoking, but not alcohol, is associated with risk of psoriasis in a Taiwanese population-based cohort study. Journal of the American Academy of Dermatology, 2019, 80, 727-734.	1.2	53
18	HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA) Journal of Clinical Oncology, 2020, 38, 638-638.	1.6	51

#	Article	IF	Citations
19	Update on treatment of gastric cancer. Journal of the Chinese Medical Association, 2014, 77, 345-353.	1.4	45
20	The association of physical activity with all-cause, cardiovascular, and cancer mortalities among older adults. Preventive Medicine, 2015, 72, 23-29.	3.4	37
21	Validation of the albuminâ€bilirubin gradeâ€based integrated model as a predictor for sorafenibâ€failed hepatocellular carcinoma. Liver International, 2018, 38, 321-330.	3.9	37
22	CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. Future Oncology, 2019, 15, 1295-1302.	2.4	37
23	Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: A populationâ€based cohort study. Cancer, 2015, 121, 1446-1455.	4.1	36
24	Cognitive impairment assessed at annual geriatric health examinations predicts mortality among the elderly. Preventive Medicine, 2014, 67, 28-34.	3.4	35
25	Clinical significance of serum autoâ€antibodies in Chinese patients with chronic hepatitis C: Negative role of serum viral titre and genotype. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 475-479.	2.8	32
26	Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLIâ€1 study. Cancer Science, 2020, 111, 513-527.	3.9	32
27	A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 637-642.	2.3	31
28	High Serum Uric Acid Levels Are Associated with Allâ€Cause and Cardiovascular, but Not Cancer, Mortality in Elderly Adults. Journal of the American Geriatrics Society, 2015, 63, 1829-1836.	2.6	31
29	Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. International Journal of Biological Sciences, 2016, 12, 1523-1532.	6.4	31
30	Albumin levels and cause-specific mortality in community-dwelling older adults. Preventive Medicine, 2018, 112, 145-151.	3.4	31
31	Cytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization. Hepatology International, 2013, 7, 883-892.	4.2	30
32	Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Medical Oncology, 2008, 25, 201-206.	2.5	28
33	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. British Journal of Cancer, 2018, 119, 19-26.	6.4	28
34	Endothelial-mesenchymal transition harnesses HSP90α-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma. Journal of Hematology and Oncology, 2019, 12, 138.	17.0	28
35	Helicobacter pylori-induced chronic inflammation causes telomere shortening of gastric mucosa by promoting PARP-1-mediated non-homologous end joining of DNA. Archives of Biochemistry and Biophysics, 2016, 606, 90-98.	3.0	25
36	Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Scandinavian Journal of Gastroenterology, 2008, 43, 992-999.	1.5	24

#	Article	IF	CITATIONS
37	Hospice Offers More Palliative Care but Costs Less Than Usual Care for Terminal Geriatric Hepatocellular Carcinoma Patients: A Nationwide Study. Journal of Palliative Medicine, 2013, 16, 780-785.	1.1	24
38	Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial. European Journal of Cancer, 2018, 105, 71-78.	2.8	24
39	The risk of irritable bowel syndrome in patients with endometriosis during a 5-year follow-up: a nationwide population-based cohort study. International Journal of Colorectal Disease, 2015, 30, 907-912.	2.2	23
40	Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours. Gut, 2022, 71, 1843-1855.	12.1	21
41	Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. Hepatology International, 2012, 6, 753-762.	4.2	20
42	The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan. PLoS ONE, 2015, 10, e0130993.	2.5	20
43	Cigarette Smoking, Alcohol Consumption, and Risk of Alopecia Areata: A Population-Based Cohort Study in Taiwan. American Journal of Clinical Dermatology, 2020, 21, 901-911.	6.7	20
44	Active Vitamin D ₃ Treatment Attenuated Bacterial Translocation via Improving Intestinal Barriers in Cirrhotic Rats. Molecular Nutrition and Food Research, 2021, 65, e2000937.	3.3	20
45	Comorbidity profiles of psoriasis in Taiwan: A latent class analysis. PLoS ONE, 2018, 13, e0192537.	2.5	19
46	Myeloid-derived macrophages and secreted HSP90 $\hat{l}\pm$ induce pancreatic ductal adenocarcinoma development. Oncolmmunology, 2018, 7, e1424612.	4.6	18
47	Differential modulation of endogenous cannabinoid CB1 and CB2 receptors in spontaneous and splice variants of ghrelin-induced food intake in conscious rats. Nutrition, 2015, 31, 230-235.	2.4	17
48	Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2) Journal of Clinical Oncology, 2017, 35, 343-343.	1.6	17
49	Metallic Stent Expansion Rate at Day One Predicts Stent Patency in Patients with Gastric Outlet Obstruction. Digestive Diseases and Sciences, 2017, 62, 1286-1294.	2.3	16
50	The Risk of Mortality among Psoriatic Patients with Varying Severity: A Nationwide Population-Based Cohort Study in Taiwan. International Journal of Environmental Research and Public Health, 2018, 15, 2622.	2.6	16
51	Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Journal of Clinical Oncology, 2015, 33, 234-234.	1.6	16
52	Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. European Journal of Cancer, 2022, 166, 208-218.	2.8	16
53	The Unusual Presentation of Gastric Adenocarcinoma as a Testicular Mass: A Favorable Response to Docetaxel and Cisplatin Plus Oral Tegafur/Uracil and Leucovorin. Journal of the Chinese Medical Association, 2010, 73, 88-92.	1.4	15

Self-Expandable Metallic Stent Placement in Malignant Gastric Outlet Obstruction. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf

#	Article	IF	CITATIONS
55	Akt phosphorylates myc-associated zinc finger protein (MAZ), releases P-MAZ from the p53 promoter, and activates p53 transcription. Cancer Letters, 2016, 375, 9-19.	7.2	15
56	Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study. Diabetes Research and Clinical Practice, 2021, 171, 108546.	2.8	15
57	A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 799-806.	2.3	14
58	Evaluation of prognostic factors and implication of lymph node dissection in intrahepatic cholangiocarcinoma: 10-year experience at a tertiary referral center. Journal of the Chinese Medical Association, 2017, 80, 140-146.	1.4	14
59	Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2. Theranostics, 2020, 10, 201-217.	10.0	13
60	Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. Cancers, 2022, 14, 218.	3.7	13
61	Obesity, but Not Metabolic Diseases, Is Associated with Risk of Psoriasis: A Population-Based Cohort Study in Taiwan. Dermatology, 2020, 236, 521-528.	2.1	12
62	A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. British Journal of Cancer, 2022, 126, 1018-1026.	6.4	11
63	What Constitutes Normal Hemoglobin Concentrations in Communityâ€Dwelling Older Adults?. Journal of the American Geriatrics Society, 2016, 64, 1233-1241.	2.6	10
64	Does Pay-For-Performance Program Increase Providers Adherence to Guidelines for Managing Hepatitis B and Hepatitis C Virus Infection in Taiwan?. PLoS ONE, 2016, 11, e0161002.	2.5	10
65	The Impact of COVID-19 Pandemic on the Learning Outcomes of Medical Students in Taiwan: A Two-Year Prospective Cohort Study of OSCE Performance. International Journal of Environmental Research and Public Health, 2022, 19, 208.	2.6	10
66	Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAgâ€positive cancer patients undergoing chemotherapy. Journal of Viral Hepatitis, 2018, 25, 1599-1607.	2.0	9
67	CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC) Journal of Clinical Oncology, 2017, 35, TPS4148-TPS4148.	1.6	9
68	Concurrence of UGT1A Polymorphism and End-Stage Renal Disease Leads to Severe Toxicities of Irinotecan in a Patient with Metastatic Colon Cancer. Tumori, 2011, 97, 243-247.	1.1	8
69	Psoriasis is not a risk factor for dementia: a 12-year nationwide population-based cohort study. Archives of Dermatological Research, 2020, 312, 657-664.	1.9	8
70	Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies. World Journal of Gastroenterology, 2004, 10, 2468.	3.3	8
71	Outcomes of enteral metallic stent in patients with pancreatic carcinoma and gastric outlet obstruction: A single center experience. Journal of the Formosan Medical Association, 2020, 119, 238-246.	1.7	7
72	A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2012, 70, 583-590.	2.3	6

#	Article	IF	CITATIONS
73	TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma Journal of Clinical Oncology, 2021, 39, 4143-4143.	1.6	6
74	Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI,) Tj ETQq0 C pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Journal of Clinical Oncology, 2016, 34, 417-417.	0 rgBT /Ove 1.6	rlock 10 Tf 50 6
75	Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience. Journal of the Chinese Medical Association, 2022, 85, 42-50.	1.4	6
76	Neurological Cancer is a Risk Factor for Bullous Pemphigoid: 11-Year Population-Based Cohort Study. American Journal of Clinical Dermatology, 2020, 21, 591-597.	6.7	5
77	Outcome for selfâ€expandable metal stents inÂpatientsÂwith malignant gastroduodenal obstruction: A single center experience. Advances in Digestive Medicine, 2014, 1, 1-8.	0.2	4
78	The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients. Journal of the Chinese Medical Association, 2018, 81, 593-598.	1.4	4
79	Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5â€fluorouracil and leucovorin. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 670-681.	2.6	4
80	Outcomes of patients with malignant duodenal obstruction after receiving self-expandable metallic stents: A single center experience. PLoS ONE, 2022, 17, e0268920.	2.5	4
81	Oncogenic circuit constituted by Ser31-HBx and Akt increases risks of chronic hepatitis and hepatocellular carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 837-849.	3.8	3
82	Prolonged bleeding time: A new clinical manifestation of hepatocellular carcinoma?. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 563-568.	2.8	2
83	Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 7545-7554.	1.5	2
84	Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study Journal of Clinical Oncology, 2022, 40, TPS4186-TPS4186.	1.6	2
85	The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 917-928.	3.8	1
86	The clinical significance of esophagogastric varices in patients with advanced pancreatic cancer. Journal of the Chinese Medical Association, 2021, Publish Ahead of Print, 917-922.	1.4	1
87	The prognostic value of baseline neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV Journal of Clinical Oncology, 2017, 35, e15795-e15795.	1.6	1
88	Outcomes of Patients with Malignant Esophagogastric Junction Obstruction Receiving Metallic Stents. Journal of the Chinese Medical Association, 2021, Publish Ahead of Print, .	1.4	1
89	Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy Journal of Clinical Oncology, 2018, 36, 410-410.	1.6	1
90	A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma. Medicine (United States), 2016, 95, e2565.	1.0	0

#	Article	IF	CITATIONS
91	Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI,) Tj ETQq1 1 cancer (mPAC) previously treated with gemcitabine (gem)-based therapy Journal of Clinical Oncology, 2016. 34, 4126-4126.	0.784314 1.6	1 rgBT /Over 0
92	Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI;) Tj ETQq0 0 0 rg	gBT6/Overlo	o o k 10 Tf 50
93	Strategic Decoy Peptides Interfere with MSI1/AGO2 Interaction to Elicit Tumor Suppression Effects. Cancers, 2022, 14, 505.	3.7	0
94	A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma Journal of Clinical Oncology, 2022, 40, 550-550.	1.6	0
95	The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan American Journal of Cancer Research, 2022, 12, 1884-1898.	1.4	0
96	Comparison between residents with a 6-year medical program and a 7-year medical program in terms of objective structured clinical examination performance in postgraduate year training in Taiwan: a 2-group pre- and post-test non-synchronized study. Journal of Educational Evaluation for Health Professions, 0, 19, 13.	12.6	0